Health Discovery Corp Licenses New Prostate Cancer Test to Abbott
|
HDC Licenses Biomarkers for Urine-Based Prostate Cancer Test to Quest Diagnostics
|
Health Discovery Corporation announced that it has entered into an agreement with Abbott (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer. Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
Read full Press Release |
Health Discovery Corporation, a molecular diagnostics company, today announced that it has licensed rights to develop a new urine-based test for clinically significant prostate cancer to Quest Diagnostics Incorporated (NYSE: DGX) , the world’s leading provider of diagnostic testing, information and services. Under the terms of the agreement, HDC will receive payments, royalties and additional undisclosed financial considerations.
Read full Press Release |
Clarient Launches Gene Expression Test for Prostate Cancer
|
HDC Signs Deal to Develop Breast Cancer Test |
Gene Profile Discovered By Health Discovery Corporation Will Provide Molecular Confirmation of Gleason Grade 3 and 4 Cancer Cells in Prostate Biopsies
Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient’s PATHSiTE(TM) virtual reporting tool and accessible to the company’s entire pathology network.
Read full Press Release |
Smart Personalized Medicine, LLC, Founded by Dr. Richard Caruso, Chairman of Integra Life Sciences (NasdaqGS: IART), Signs Agreement with Health Discovery Corporation to Develop New Breast Cancer Prognostic Test.
Health Discovery Corporation to Receive a Fifteen Percent Equity Position in Smart Personalized Medicine, LLC and Will Receive Royalties Paid on a Per Test Basis from Breast Cancer Prognostic Tests Performed.
Read full Press Release
|
| HDC Develops Tests for Ovarian Cancer, Cervical Cancer and Endometrial Cancer |
HDC Inks Agreement with PPI for Monetization of Patent Portfolio |
New Computer Assisted Diagnostic Tests for Ovarian Cancer, Cervical Cancer and Endometrial Cancer to be Jointly Developed by Health Discovery Corporation and DCL Medical Laboratories.
Health Discovery Corporation and DCL Medical Laboratories will Develop and Commercialize new Digital Pathology Diagnostics for Ovarian Cancer, Cervical Cancer and Endometrial Cancer.
Read full Press Release |
Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio.
Health Discovery Corporation, a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.
Read full Press Release |
| HDC' Licenses SVM Technology to Pfizer |
HDC's Extensive Patent Portfolio |
|
Health Discovery Corporation Announces Worldwide License Agreement With Pfizer.
Health Discovery Corporation announces a license agreement with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer may access HDC’s pattern recognition technology for use in its worldwide research and development activities. The license includes HDC’s Support Vector Machine (“SVM”), Fractal Genomic Modeling (“FGM”), and related methods for data analysis.
Read full Press Release
|
HDC's Patent Portfolio Includes:
31 Issued Patents
52 Pending Patents
View full Patent Portfolio |
| HDC' Successful In Patent Infringement Lawsuits |
HDC & Atlantic Alpha Strategies, LLC Form Joint Venture in Investment Analysis. |
Health Discovery Corporation Settles Patent Infringement Suit against Ciphergen Biosystems, Inc.
Health Discovery Corporation announced that its patent infringement action against Ciphergen Biosystems, Inc. has been settled. Under the terms of the agreement, Ciphergen will pay $600,000 to HDC and receive a non-exclusive license to use HDC's support vector machines in applications for Ciphergen's proprietary SELDI-based technologies.
Read full Press Release
Health Discovery Corporation Obtains Consent Judgment in Patent Lawsuit Atainst Equbits LLC.
Equbits to Cease Use of HDC’s Patented SVM Technology.
Read full Press Release |
Health Discovery Corporation and Atlantic Alpha Strategies, LLC Announce Formation of Joint Venture.
New Company Will Apply HDC’s State-of-the-Art Support Vector Machine Technology to Quantitative Investment Analysis.
Health Discovery Corporation announced that it had entered into a binding agreement with Atlantic Alpha Strategies, LLC to explore and exploit the potential applicability of HDC’s Support Vector Machines (“SVM”) to quantitative investment management techniques. An equally owned joint venture, SVM Capital LLC, will be formed to advance these objectives. Among other considerations, HDC will contribute a worldwide exclusive license for the use of SVMs in financial markets and Atlantic Alpha will contribute an historical database for equity, debt, currency and commodities markets.
Read full Press Release |
